GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
NEW YORK, Oct. 31, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased MGT Capital Investments, Inc. (NYSE MKT:MGT) securities between May 9, 2016 and September 20, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/mgt-capital-investments-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company was engaging in and/or had engaged in conduct that would result in an SEC investigation; (b) the SEC investigation and the underlying conduct would cause the New York Stock Exchange to refuse to list the Company’s 43.8 million shares required for the D-Vasive merger; and (c) as such, the D-Vasive merger would likely not be completed.
On September 19, 2016, MGT announced the receipt of a subpoena from the SEC requesting information from the Company. In addition, the Company announced that the NYSE has refused to list the shares required to close MGT’s acquisition of D-Vasive Inc. Following this news, shares of MGT fell from a close of $2.52 the previous day to a close of $1.89 per share on September 20, 2016.
If you suffered a loss in MGT you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/mgt-capital-investments-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
